JP2009506080A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009506080A5 JP2009506080A5 JP2008528306A JP2008528306A JP2009506080A5 JP 2009506080 A5 JP2009506080 A5 JP 2009506080A5 JP 2008528306 A JP2008528306 A JP 2008528306A JP 2008528306 A JP2008528306 A JP 2008528306A JP 2009506080 A5 JP2009506080 A5 JP 2009506080A5
- Authority
- JP
- Japan
- Prior art keywords
- effective amount
- therapeutic effect
- receptor agonist
- opioid receptor
- antagonize
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003402 opiate agonist Substances 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- 230000002708 enhancing Effects 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
Claims (1)
- 治療効果を生じる有効量のオピオイド受容体アゴニストと、オピオイド受容体アゴニストの治療効果を拮抗しないが増強する有効量のα-2受容体アンタゴニストとを含む組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71254505P | 2005-08-30 | 2005-08-30 | |
US75395805P | 2005-12-23 | 2005-12-23 | |
PCT/CA2006/001441 WO2007025383A1 (en) | 2005-08-30 | 2006-08-30 | Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2 receptor antagonist |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009506080A JP2009506080A (ja) | 2009-02-12 |
JP2009506080A5 true JP2009506080A5 (ja) | 2009-10-22 |
Family
ID=37808435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008528306A Pending JP2009506080A (ja) | 2005-08-30 | 2006-08-30 | 超低用量のα−2−受容体アンタゴニストを用いる、オピオイド受容体アゴニストの治療作用の増強方法および/またはオピオイド受容体アゴニストに対する耐性の阻害方法もしくは逆転方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070060501A1 (ja) |
EP (1) | EP1942903A4 (ja) |
JP (1) | JP2009506080A (ja) |
AU (1) | AU2006287070A1 (ja) |
CA (1) | CA2627158A1 (ja) |
IL (1) | IL189869A0 (ja) |
WO (1) | WO2007025383A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
CN104383542B (zh) * | 2003-04-08 | 2017-09-26 | 普罗热尼奇制药公司 | 包含甲基纳曲酮的药物配方 |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
JP5241484B2 (ja) * | 2005-03-07 | 2013-07-17 | ザ ユニヴァーシティー オヴ シカゴ | 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用 |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
WO2007057508A2 (en) * | 2005-11-18 | 2007-05-24 | Orion Corporation | Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol |
CA2657481A1 (en) * | 2006-07-21 | 2008-01-24 | Queen's University At Kingston | Methods and therapies for potentiating a therapeutic action of an alpha- 2 adrenergic receptor agonist and inhibiting and/or reversing tolerance to alpha- 2 adrenergic receptor agonists |
TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
PE20130480A1 (es) | 2007-03-29 | 2013-05-08 | Progenics Pharm Inc | Compuestos heterociclicos como antagonistas del receptor opioide periferico |
EP3263571B2 (en) * | 2007-03-29 | 2023-08-23 | Progenics Pharmaceuticals, Inc. | Crystal form of (r)-n-methylnaltrexone bromide and uses thereof |
US8338446B2 (en) | 2007-03-29 | 2012-12-25 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
WO2009099411A1 (en) * | 2008-02-06 | 2009-08-13 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
AU2009225434B2 (en) * | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
CA2676881C (en) * | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
WO2010074753A1 (en) | 2008-12-23 | 2010-07-01 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
WO2010148519A1 (en) * | 2009-06-25 | 2010-12-29 | Queen's University At Kingston | Methods and therapies for alleviating pain comprising an ultra low dose of an alpha 2 receptor antagonist |
US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US20170216277A1 (en) * | 2016-01-06 | 2017-08-03 | Trevi Therapeutics, Inc. | Therapeutic use of nalbuphine without aquaretic effects |
WO2020023486A1 (en) | 2018-07-23 | 2020-01-30 | Trevi Therapeutics, Inc. | Treatment of chronic cough, breathlessness and dyspnea |
US20220160704A2 (en) * | 2018-08-08 | 2022-05-26 | Torralva Medical Therapeutics Llc | Compositions for opiate and opioid prevention and reversal, and methods of their use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI81092C (fi) * | 1986-05-15 | 1990-09-10 | Farmos Oy | Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat. |
US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
US5855907A (en) * | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
DE19758564A1 (de) * | 1997-11-11 | 1999-08-26 | Gruenenthal Gmbh | Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung |
US6057368A (en) * | 1998-08-05 | 2000-05-02 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
AU2001294808A1 (en) * | 2000-09-29 | 2002-04-08 | Board Of Trustees Operating Michigan State University | Catecholamine pharmaceutical compositions and methods |
US20060058364A1 (en) * | 2002-03-29 | 2006-03-16 | Antti Haapalinna | Treatment of dependence and dependence related withdrawal symptoms |
-
2006
- 2006-08-30 JP JP2008528306A patent/JP2009506080A/ja active Pending
- 2006-08-30 EP EP06790619A patent/EP1942903A4/en not_active Withdrawn
- 2006-08-30 CA CA002627158A patent/CA2627158A1/en not_active Abandoned
- 2006-08-30 WO PCT/CA2006/001441 patent/WO2007025383A1/en active Search and Examination
- 2006-08-30 US US11/515,301 patent/US20070060501A1/en not_active Abandoned
- 2006-08-30 AU AU2006287070A patent/AU2006287070A1/en not_active Abandoned
-
2008
- 2008-02-28 IL IL189869A patent/IL189869A0/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009506080A5 (ja) | ||
NO2020027I1 (no) | glasdegib, eventuelt i form av et farmasøytisk akseptabelt salt, inkludert maleatsaltet | |
EP2054411A4 (en) | NOVEL COMPOUNDS, ISOMERS THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
EP2121658A4 (en) | PIPERAZINYLPROPYLPYRAZOL DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
IL189869A0 (en) | Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptor agonists using an ultralow dose of an alpha-2 receptor antagonist | |
NO343776B1 (no) | Forbindelse som modulerer farmakokinetikkegenskaper til terapeutika, dens anvendelse i terapi og farmasøytisk sammensetning derav. | |
MX2009009201A (es) | Composicion farmaceutica. | |
CL2007001992A1 (es) | Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege | |
EP2045251A4 (en) | COMPOUNDS WHICH CAN INCLUDE THE UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS | |
CL2007003265A1 (es) | Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras. | |
IL192426A0 (en) | Prokineticin 2 receptor antagonists | |
AP2008004441A0 (en) | Piperdin-4-ylpyrazin-2-ylamine derivatives as fastdissociating dopamine 2 receptor antagonists | |
EP2170064A4 (en) | 6,5-pyrrolopiperidine tachykinin receptor antagonists | |
BRPI0915411A2 (pt) | partículas revestidas contendo agentes farmaceuticamente ativos | |
HRP20150661T1 (en) | Peripheral opioid receptor and antagonists and uses thereof | |
PL2137191T3 (pl) | Antagoniści obwodowego receptora opioidowego i ich zastosowania | |
CL2013001943A1 (es) | Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma. | |
JP2006305390A5 (ja) | ||
EP1808446A4 (en) | IL-18 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION WITH THE ANTAGONIST | |
DK2121630T3 (da) | Hurtigt dissocierende dopamin-2-receptor-antagonister | |
PL2238110T3 (pl) | Pochodne 5,6-bisarylo-2-pirydyno-karboksamidu, ich wytwarzanie i ich zastosowanie terapeutyczne jako antagonistów receptora Urotensyny II | |
HK1129595A1 (zh) | 受體激動劑 可樂定 與抗毒蕈碱藥 奧昔布寧 聯合用於治療流涎 | |
JP2009522279A5 (ja) | ||
IL192270A0 (en) | Substituted oxadiazole derivatives and their use as opioid receptor ligands | |
CL2007002611A1 (es) | Compuestos derivados de eter diarilico, antagonistas de los receptores opioides mu, kappa y delta; composicion farmaceutica; y uso para el tratamiento de la obesidad. |